Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Psoriatic arthritis (PsA) is a chronic, systemic inflammatory arthritis with symptoms spanning six domains including peripheral arthritis, enthesitis, dactylitis, axial disease, psoriasis, and nail disease. The classification of disease has been refined over recent years following the development of criteria such as ClASsification of PsA criteria. In addition to classification, treatment options for PsA have continued to expand over recent years, with the development of monoclonal antibody therapies targeting the underlying immunological mediators involved in PsA such as interleukin (IL)-17, tumor necrosis factor-alpha, and IL-23. Therapies have shown that robust treatment in patients, achieving tight disease control, improves outcomes and overall quality of life. This review provides a broad overview of the epidemiology, classification, and treatment of PsA.

Original publication




Journal article


Indian journal of rheumatology

Publication Date





S45 - S51